US Corporate Distress Financial Stress SEC Filings — July 07, 2026

07-07-2026

21Shares Dogecoin ETF (TDOG) announced the termination of its pricing benchmark licensing agreement with CF Benchmarks, effective August 31, 2026, as part of a transition to a new benchmark provider. The sponsor intends to enter into a licensing agreement with FTSE International Limited on or about August 24, 2026, to use FTSE index data for valuation and NAV calculation. This change does not involve any financial figures or performance metrics, and no positive or negative financial impact is disclosed.

• · The Pricing Benchmark Licensing Agreement has a one-year initial term and automatically renews for successive one-year periods unless terminated.
• · The new FTSE licensing agreement is expected to have a one-year initial term and will automatically renew for successive one-year periods unless terminated.
• · FTSE is a company incorporated and registered in England, with principal offices at 10 Paternoster Square, London, EC4M 7LS, United Kingdom.
• · FTSE is experienced in calculating and administering digital asset indices and is unaffiliated with the Sponsor.

07-07-2026

MasTec, Inc. and its subsidiary MasTec North America, Inc. entered into a Term Loan Agreement on July 7, 2026, with Bank of America as Administrative Agent and several other lenders, establishing two term loan facilities (Three-Year and Four-Year). The agreement includes customary representations, covenants (including a Consolidated Leverage Ratio covenant), events of default, and provisions for interest rates based on the Company's leverage ratio and debt ratings. No specific dollar amounts for the facilities are disclosed in the filing excerpt.

• · The agreement includes a Consolidated Leverage Ratio negative covenant (Section 7.09).
• · Interest rates are determined by a grid referencing the Company's Consolidated Leverage Ratio and Debt Ratings from S&P and Moody's, with a mechanism to resolve splits between the two.
• · The agreement provides for joint and several liability of the two borrowers (Section 2.14).
• · The filing includes exhibits such as forms of Loan Notice, Note, Compliance Certificate, Assignment and Assumption, and Solvency Certificate.

07-07-2026

Vertex Pharmaceuticals announced the acquisition of Crinetics Pharmaceuticals for $85 per share in cash, totaling approximately $10 billion ($8.8 billion net of cash). The deal adds potential best-in-class endocrinology assets including PALSONIFY (approved once-daily oral for acromegaly, launched October 2025 with strong early uptake) and atumelnant (Phase 3 for congenital adrenal hyperplasia). Vertex expects the acquisition to accelerate revenue growth and support sustained double-digit growth, with the transaction becoming accretive to non-GAAP operating income in 2029. However, the deal carries integration risks, requires regulatory and stockholder approvals, and the pipeline assets remain subject to clinical and commercial uncertainties.

• · PALSONIFY is FDA and EMA approved; U.S. launch occurred in October 2025.
• · Atumelnant is in Phase 3 for adults and Phase 2/3 for pediatric CAH, and Phase 2 for ACTH-dependent Cushing's syndrome.
• · Crinetics has IP protection into the 2040s.
• · Crinetics was founded in 2008 and is headquartered in San Diego, CA.
• · Only ~40-50% of acromegaly patients achieve durable remission with surgery.
• · Only 18% of patients remain on injectable SRLs at ~3 years, indicating high discontinuation.
• · PALSONIFY is indicated for both treatment-naïve and switch patients.
• · Vertex expects the transaction to be accretive to non-GAAP operating income in 2029.
• · The acquisition is supported by fully committed bridge financing.

07-07-2026

Vroom, Inc. announced an amendment to its warehouse credit facility on June 30, 2026. The amendment extends the commitment termination date from July 2, 2026 to June 2, 2027, and modifies financial covenants, including increasing the maximum permitted leverage ratio and maximum advance rate, while simplifying the minimum tangible net worth threshold. In connection with this amendment, Vroom Finance Holdings LLC entered into a performance guaranty for obligations under the facility.

• · Amendment No. 29 modifies the warehouse credit facility originally dated November 19, 2013.
• · The amendment increases the maximum permitted leverage ratio and the maximum advance rate.
• · The minimum tangible net worth threshold is simplified and reduced.
• · The performance trigger framework has been updated.
• · Vroom Finance Holdings LLC provided a Performance Guaranty for the facility obligations.

07-07-2026

Solstice Advanced Materials Inc. (Parent) has entered into a definitive Agreement and Plan of Merger to acquire Element Solutions Inc (Company) through a two-step merger process structured as a tax-free reorganization under Section 368(a) of the Code. The transaction will be effected via a first merger of a wholly-owned subsidiary into Element Solutions, followed immediately by a second merger into another subsidiary, with Element Solutions stockholders receiving Parent stock and three designated Company directors joining the Parent board. The closing is conditioned on stockholder approvals, regulatory clearances, and other customary conditions, with a potential delay option for Parent if conditions are satisfied after December 6, 2026.

• · The merger is structured as two sequential mergers: first Merger Sub One merges into Element Solutions, then the surviving corporation merges into Merger Sub Two.
• · The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the Code.
• · Parent may delay the closing until January 4, 2027, if the closing condition satisfaction date occurs after December 6, 2026 and before January 1, 2027.
• · Three Designated Directors from Element Solutions' board will join the Parent board of directors (expanded to 11 members) as of the First Merger Effective Time.
• · Concurrently with the agreement, certain Element Solutions stockholders entered into a Voting and Support Agreement in favor of Parent.
• · The agreement includes customary representations, warranties, covenants, and conditions precedent for both parties, including no material adverse effect clauses.

07-07-2026

Vivani Medical announced a non-exclusive agreement with Novo Nordisk to evaluate NPM-139, its semaglutide implant for chronic weight management. The agreement has no exclusivity provisions for NPM-139 or Vivani's NanoPortal technology. Separately, Vivani expects to initiate a Phase 1 first-in-human study of NPM-139 in mid-2026, with Wegovy as an active comparator. While the partnership signals Novo Nordisk's interest, the non-exclusive nature limits immediate financial upside, and the Phase 1 study has yet to begin.

• · The agreement is non-exclusive with no exclusivity provisions for NPM-139 or NanoPortal technology.
• · Phase 1 study expected to start mid-2026, with Wegovy as active comparator.
• · Study objectives include safety, pharmacokinetics, and tolerability to support Phase 2 dose-ranging study.
• · Vivani's NanoPortal implants aim for once- or twice-yearly dosing with ability to stop treatment if needed.

07-07-2026

MeiraGTx announced a strategic investment of up to $400 million from Oberland Capital, comprising up to $375 million in non-dilutive royalty funding and up to $25 million in equity. The initial $135 million funded includes $125 million for low single-digit capped royalties on three late-stage programs (AAV2-hAQP1, bota-vec, AAV-AIPL1) and a $10 million equity investment, with additional tranches tied to data readouts and regulatory approvals through 2028. While the deal provides substantial non-dilutive capital to support commercialization, the royalty payments are capped at a multiple of funded amounts, and the company remains in a clinical-stage, pre-revenue position with significant ongoing risks.

• · Royalty payments are capped at a multiple of the amounts funded.
• · The agreement includes flexible provisions for potential change of control, with the ability for MeiraGTx to buy back the entire funded royalty note at any time by paying certain specified amounts.
• · Oberland Capital has the right to purchase an additional $15 million in equity in MeiraGTx.
• · MeiraGTx has four late-stage clinical programs, including one for Parkinson's disease.
• · MeiraGTx has developed a proprietary riboswitch gene regulation technology for in vivo delivery of biologic therapeutics using oral small molecules.

07-07-2026

Frontier Group Holdings, Inc. entered into a definitive agreement with Avolon to sell 11 A321neo aircraft from its existing purchase commitment as part of a fleet-rightsizing initiative. The sale includes 3 deliveries expected in Q4 2026 and 8 in the first half of 2027, with aircraft sold at current market rates factoring in transition costs. As a result, Frontier now expects to take delivery of 22 aircraft in 2026 (8 A320neo and 14 A321neo, with 3 of the A321neo sold) and exit the year with a fleet of 171 aircraft.

• · The agreement was previously disclosed as a non-binding agreement in principle on May 5, 2026.
• · The aircraft are sold at current market rates factoring in transition-related costs, including estimated remarketing costs.
• · Each aircraft will be sold at the time of delivery to the Company.

07-07-2026

StageWise Strategies Corp. entered into a Share Subscription Agreement with its controlling shareholder Jakhongir Abidovich Artikkhodjaev, who currently owns approximately 74.2% of the company, to issue 1,000,000 shares of common stock for an aggregate purchase price of $250,000. A partial payment of $44,500 was received on June 30, 2026, with the remaining $205,500 expected by July 31, 2026. The transaction is a private placement exempt from registration under Section 4(a)(2) of the Securities Act, and the shares will be restricted securities.

• · The subscriber is a controlling shareholder owning approximately 74.2% of the company prior to the issuance.
• · The shares are restricted securities under Rule 144(a)(3) and will bear a restrictive legend.
• · The subscriber represented that he is an accredited investor and is acquiring the shares for investment purposes.
• · No broker, finder, or other financial consultant acted on behalf of either party in connection with the agreement.
• · The agreement is governed by the laws of the State of Nevada.

07-07-2026

VSee Health, Inc. entered into a Securities Purchase Agreement with ClearThink Capital Partners, LLC on June 17, 2026, issuing a promissory note with an aggregate principal amount of $280,000 (including a $30,000 original issue discount) in exchange for net proceeds of $250,000. The note is convertible into common shares (par value $0.0001 per share) and is being sold in reliance on an exemption from registration under the Securities Act. The company has 47,299,421 shares outstanding out of 100,000,000 authorized shares, and no material adverse changes have been reported since December 31, 2025.

• · The securities are being sold under an exemption from registration under the Securities Act of 1933, relying on Regulation D accredited investor rules.
• · The note bears a restrictive legend and can only be transferred under an effective registration statement or with a legal opinion acceptable to the company.
• · The company represents that it has filed all required SEC reports and that its financial statements comply with GAAP.
• · No material adverse change has occurred since December 31, 2025, according to the company's representation.
• · The company is not an investment company under the Investment Company Act of 1940.

07-07-2026

RPC Inc. entered into an amended and restated credit agreement dated June 30, 2026, with Bank of America as administrative agent, Truist Bank and PNC Bank as co-syndication agents, and other lenders, replacing the existing credit agreement from August 31, 2010. The new agreement provides for a revolving credit facility with pricing based on the company's consolidated leverage ratio, with commitment fees ranging from 0.200% to 0.300% and interest spreads from 1.250% to 2.250% for Term SOFR loans plus letters of credit. Specific aggregate commitment amounts are not disclosed in the filing excerpt.

• · The agreement amends and restates the existing credit agreement dated August 31, 2010.
• · The credit facility includes revolving loans, swing line loans, and letters of credit.
• · Advance limits are subject to a borrowing base calculation during periods when Consolidated EBITDA is less than $50 million.
• · The total aggregate commitments are not specified in this filing excerpt; the schedule of commitments (Schedule 2.01) is referenced but not included.
• · Pricing is determined by a five-level grid based on the Consolidated Leverage Ratio, with an initial Pricing Level 1 applied until delivery of the compliance certificate for the quarter ending June 30, 2026.

07-07-2026

21Shares Sui ETF (TSUI) is terminating its benchmark licensing agreement with CF Benchmarks Ltd., effective August 31, 2026, as part of a broader transition to a new benchmark provider. The sponsor intends to enter into a licensing agreement with FTSE International Limited (FTSE) on or about August 24, 2026, to use FTSE index data for the Trust. This change in benchmark provider may introduce operational and valuation adjustments, but no financial impact or performance data is disclosed.

• · The Pricing Benchmark Licensing Agreement with CF Benchmarks has a one-year initial term and auto-renews unless terminated.
• · The new FTSE license is expected to have a one-year initial term with automatic renewal.
• · FTSE is experienced in calculating and administering digital asset indices and is unaffiliated with the Sponsor.
• · The termination notice was provided on June 30, 2026, with an effective date of August 31, 2026.

07-07-2026

21Shares Polkadot ETF (TDOT) is terminating its benchmark licensing agreement with CF Benchmarks Ltd., effective August 31, 2026, as part of a transition to a new benchmark provider. The sponsor intends to enter a licensing agreement with FTSE International Limited around August 24, 2026, to use FTSE index data for valuation and NAV calculation. This change is a strategic shift in benchmark provider but does not involve any financial terms or performance data.

• · Termination notice was provided on June 30, 2026, with the agreement ending August 31, 2026.
• · The new FTSE licensing agreement is expected to have a one-year initial term with automatic renewal.
• · FTSE is experienced in digital asset indices and is unaffiliated with the sponsor.

07-07-2026

The 21Shares Solana ETF (TSOL) filed an 8-K on July 7, 2026, announcing the termination of its Pricing Benchmark Licensing Agreement with CF Benchmarks, effective August 31, 2026. The sponsor plans to replace it with a new licensing agreement with FTSE International Limited, expected to be in place by August 24, 2026, marking a benchmark provider transition. No financial figures were disclosed in this filing, and there is no indication of any negative impact; rather, the move suggests a strategic operational update.

• · The Pricing Benchmark Licensing Agreement had a one-year initial term with automatic renewals.
• · CF Benchmarks is unaffiliated with the sponsor.
• · The new FTSE agreement is expected to have a one-year initial term and automatic renewal.
• · FTSE is a UK-based company, experienced in digital asset indices, and unaffiliated with the sponsor.
• · The termination and transition are described as a broader move to a new benchmark provider.

07-07-2026

Ark 21Shares Bitcoin ETF (ARKB) announced the termination of its Pricing Benchmark Licensing Agreement with CF Benchmarks Ltd., effective August 31, 2026, as part of a transition to a new benchmark provider. The sponsor intends to enter a licensing agreement with FTSE International Limited around August 24, 2026, to use FTSE index data for valuation and NAV calculation. This change in benchmark provider does not involve any financial figures or performance metrics, but represents a material operational shift for the ETF.

• · The Pricing Benchmark Licensing Agreement had a one-year initial term with automatic renewal for successive one-year periods.
• · CF Benchmarks is unaffiliated with the Sponsor.
• · FTSE is a company incorporated in England with principal offices in London.
• · FTSE is experienced in calculating and administering digital asset indices and is unaffiliated with the Sponsor.
• · The new FTSE license is expected to have a one-year initial term with automatic renewal.

07-07-2026

21Shares XRP ETF (TOXR) announced the termination of its Pricing Benchmark Licensing Agreement with CF Benchmarks, effective August 31, 2026, as part of a transition to a new benchmark provider. The sponsor intends to enter into a licensing agreement with FTSE International Limited on or about August 24, 2026, to use FTSE index data for valuation and NAV calculation. This change does not involve any financial impact or performance metrics.

• · The Pricing Benchmark Licensing Agreement has a one-year initial term and auto-renews unless terminated.
• · The new FTSE licensing agreement is expected to have a one-year initial term with automatic renewal.
• · CF Benchmarks and FTSE are both unaffiliated with the Sponsor.
• · The termination notice was provided on June 30, 2026, with an effective date of August 31, 2026.

07-07-2026

Suncrete, Inc. (RMIX) subsidiary Concrete Partners, LLC entered into a Fifth Amendment to its Credit Agreement with Bank of America as Administrative Agent, increasing the revolving facility by $25M and establishing a new $175M delayed draw term loan facility. The amendment also adds Wells Fargo and Regions Bank as new lenders. The company must maintain a Consolidated Senior Net Leverage Ratio no greater than 3.75:1.00 and at least $10M in available revolving loans after giving effect to the amendment.

• · The amendment is dated June 30, 2026 and was filed on July 7, 2026.
• · The Credit Agreement was originally dated July 29, 2024 and has been amended four times prior to this Fifth Amendment.
• · The amendment adds Wells Fargo Bank, N.A. and Regions Bank as new Lenders.
• · Conditions for effectiveness include no Material Adverse Effect since December 31, 2025 and a Solvency Certificate from the Borrower.

07-07-2026

The Children's Place, Inc. appointed Muhammad Asif Seemab as President and Interim Chief Executive Officer effective July 6, 2026, replacing his prior role as Executive Vice Chairman. The offer letter includes an annual base salary of $497,500 but notably excludes participation in the annual management incentive plan and equity incentive plan, and explicitly denies severance or separation benefits unless otherwise approved by the Board. The appointment is interim until a permanent CEO is identified, and the letter includes a 12-month non-compete clause covering major competitors.

• · Mr. Seemab will not receive any additional compensation for his continued service as a Board member while an executive.
• · The offer letter explicitly states employment is at-will and does not constitute an employment contract.
• · Mr. Seemab is subject to stock ownership guidelines adopted by the Compensation Committee.
• · The non-compete clause specifically lists major retailers and apparel companies as competitive businesses.
• · Mr. Seemab acknowledged he is a 'senior executive' under the FTC's Non-Compete Clause Rule.

07-07-2026

Intapp, Inc. entered into a Third Amended and Restated Registration Rights Agreement with investors Anderson Investments Pte. Ltd. and Aranda Investments Pte. Ltd., as well as Director John Hall, on July 1, 2026. The agreement extends the term of registration rights until the investors hold less than 5% of outstanding common stock and adds Aranda Investments as a party. The existing material terms remain substantially unchanged from the prior agreement.

• · The Third A&R Registration Rights Agreement amends and restates the Second Amended and Restated Registration Rights Agreement dated July 2, 2021.
• · The agreement extends the term until the Investor holds less than 5% of outstanding common stock.

07-07-2026

Unitil Corporation completed the purchase of two New Hampshire water companies (Aquarion Water Company of NH and Abenaki Water Co.) from Aquarion Water Authority for $55.8 million, including $13.7 million in assumed debt and $0.6 million for working capital. The acquisition adds approximately 11,000 water customers and 150 miles of water mains, expanding Unitil's regulated utility services. The deal is expected to be earnings accretive over the long term, supporting Unitil's 5% to 7% EPS growth target, though integration risks and water-related operational hazards remain.

• · The Stock Purchase Agreement was first announced on May 6, 2025 and subsequently amended to limit the purchase to the two Aquarion Companies.
• · All conditions of the Agreement, including approvals from the New Hampshire and Maine Public Utilities Commissions, were materially completed as of the closing date.
• · Unitil funded the purchase price through a term loan from Scotiabank.
• · The acquired water systems serve eight communities in New Hampshire.
• · Unitil was advised by Scotiabank and the law firm of Dentons.

07-07-2026

XMax Inc. entered into Securities Purchase Agreements on July 1, 2026, to sell 434,600 shares of common stock at $8.454 per share in a private placement, raising approximately $3.67 million. The shares are subject to an 18-month lock-up period, and the offering was conducted under Regulation S exemption for non-U.S. investors. The filing does not disclose any financial performance metrics, so no positive or negative trends can be assessed.

• · The purchase price per share was $8.454.
• · The lock-up period is 18 months from July 1, 2026.
• · The offering was exempt from registration under Regulation S of the Securities Act of 1933.
• · The filing includes a form of Securities Purchase Agreement as Exhibit 10.1.

07-07-2026

Tecnoglass Inc. (TGLS) filed an 8-K on July 7, 2026, announcing the filing of new Articles of Incorporation reincorporating from a Cayman Islands company to a Florida corporation. The charter authorizes 101 million shares (100M common + 1M preferred, both $0.0001 par value) and imposes supermajority 66⅔% vote requirements for changing certain governance provisions, including director removal and charter amendments. The reincorporation introduces new shareholder rights such as a 10% threshold for calling special meetings and eliminates the ability to remove directors without cause, likely viewed as management-friendly but standard for a Florida domicile.

• · The reincorporation shifts the meeting threshold from no specific provision to a 10% holder requirement, making it harder for shareholders to call a special meeting.
• · Directors can only be removed 'for cause' and by a majority vote of shares cast; removal without cause is eliminated.
• · Super-majority 66⅔% vote is required to alter director removal or charter amendment provisions (Articles VIII and X), which could entrench management.
• · The preferred stock can be issued in series without shareholder approval, giving the Board flexibility on terms such as dividends, liquidation preferences, and conversion rights.
• · The registered agent is NRAI Services, Inc. at 1200 South Pine Island Road, Plantation, Florida 33324.

07-07-2026

Lifeward Ltd. entered into a Securities Purchase Agreement dated June 30, 2026, with multiple purchasers and Oramed Pharmaceuticals Inc. as collateral agent, providing for the issuance and sale of Senior Secured Convertible Notes and Ordinary Share purchase warrants in a private placement exempt from registration under the Securities Act. The company will use net proceeds for working capital, general corporate purposes, commercialization efforts, and R&D, and has agreed to indemnify purchasers against certain losses. No specific dollar amounts or share counts are disclosed in this excerpt.

• · The Additional Warrants are exercisable immediately upon issuance and have a term of five years from the date of issuance.
• · The agreement includes a covenant that the Company will not provide material non-public information to purchasers without prior written consent, and any such information inadvertently provided does not impose a duty of confidentiality.
• · The Company is restricted from using proceeds for debt satisfaction (other than the Notes or ordinary trade payables), share redemptions, litigation settlements, or in violation of FCPA or OFAC regulations.
• · The Company has agreed to indemnify Purchaser Parties for losses arising from breaches of representations, warranties, or covenants, as well as certain securities law violations.

07-07-2026

21Shares Ethereum ETF (TETH) disclosed the termination of its pricing benchmark licensing agreement with CF Benchmarks, effective August 31, 2026, as part of a planned transition to a new benchmark provider. The sponsor intends to enter a licensing agreement with FTSE International Limited around August 24, 2026, to use FTSE index data for valuing the Trust's shares and calculating net asset value. The change is a strategic operational shift with no immediate financial impact disclosed.

• · The Pricing Benchmark Licensing Agreement with CF Benchmarks had a one-year initial term with automatic renewal.
• · The new FTSE licensing agreement is expected to have a one-year initial term and auto-renew.
• · FTSE is based in London, UK, and is unaffiliated with the Sponsor.
• · The Trust's shares trade on Cboe BZX Exchange under ticker TETH.
• · The registrant is an emerging growth company and has not elected to use the extended transition period for new financial accounting standards.

07-07-2026

Interactive Strength Inc. (TRNR) entered into a Settlement Agreement with Vertical Investors, LLC on June 30, 2026, issuing 225,681 shares of Series C Preferred Stock as payment for a $451,361 Net Trade Value owed under a prior Loan Restoration Agreement. The settlement resolves a shortfall where the Total Loan Exchanged Amount of approximately $9,034,431 far exceeded the Net Trade Value of $451,361, highlighting the company's ongoing financial strain and reliance on equity-based settlements.

• · The Settlement Agreement was entered into on June 30, 2026, and filed on July 7, 2026.
• · The original Credit Agreement was dated February 1, 2024, with a principal amount of $7,968,977.74.
• · On March 29, 2024, 1,500,000 shares of Series A Preferred Stock were issued upon conversion of $3.0 million of the loan.
• · The Loan Modification Agreement on April 24, 2024 reduced the principal by $3.0 million.
• · The Loan Restoration Agreement required the company to pay any shortfall if Net Trade Value was less than Total Loan Exchanged Amount by December 31, 2025.
• · The Net Trade Value of $451,361 represents only about 5% of the Total Loan Exchanged Amount of $9,034,431.
• · The issuance of Series C Preferred Shares was exempt from registration under Section 4(a)(2) of the Securities Act.

07-07-2026

Global Industrial Company (GIC) entered into Amendment No. 4 to its Third Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A. as Administrative Agent, dated June 30, 2026. The amendment modifies certain terms, schedules, and exhibits of the credit agreement and includes post-effective date covenants requiring corrective patent filings and good standing certificates for certain subsidiaries. No financial amounts or changes to credit limits were disclosed in the filing.

• · The amendment requires corrective filings with the USPTO within 30 days to fix a prior patent assignment error where patents owned by Global Industrial Distribution Inc. were erroneously recorded as owned by Global Equipment Company Inc.
• · Within 90 days, the company must use commercially reasonable efforts to obtain certificates of good standing for Indoff Holdings Inc. (Illinois and North Dakota) and Global Industrial Services, Inc. (Wisconsin and Oklahoma), and release all existing tax liens.
• · The amendment restates and reaffirms all representations and warranties of the loan parties as true and correct, with no Default or Event of Default continuing after giving effect to the amendment.
• · The amendment was executed by Thomas Clark on behalf of all borrower and guarantor entities.

07-07-2026

NextNRG, Inc. entered into a $1.0M (net $940K after $60K fee) Merchant Cash Advance agreement with Avanza Capital Holdings. The deal provides immediate liquidity against $1.5M of future receivables but carries a 25% daily settlement lock-up and 25% liquidated damages on defaults. While the financing alleviates near-term cash constraints, the high effective cost and CEO Michael Farkas's personal guarantee underscore significant credit risk.

• · Agreement is secured by a first priority security interest in all of the Company's present and future accounts, deposit accounts, accounts receivable, chattel paper, documents, equipment, general intangibles, instruments, inventory, and proceeds.
• · CEO Michael D. Farkas personally guaranteed the full performance of all representations, warranties, and covenants under the Avanza MCA.
• · Upon default, Avanza may declare the full uncollected Receivables Purchased Amount plus all fees immediately due and payable, and collect 25% of the unpaid balance as liquidated damages.
• · The Company may prepay the outstanding balance at any time without penalty.

07-07-2026

Kennedy Lewis Capital Company entered into a Custody Agreement with U.S. Bank Trust Company, National Association, effective July 1, 2026, to hold and administer the company's securities and cash in compliance with Section 17(f) of the Investment Company Act of 1940. The agreement covers the appointment of the custodian, duties, reporting, termination, and limited recourse provisions. No financial figures or period-over-period comparisons are provided in this filing.

• · The agreement is dated July 1, 2026, and was filed as an 8-K on July 7, 2026.
• · The custodian is U.S. Bank Trust Company, National Association.
• · The agreement includes provisions for foreign securities, sub-custodians, and eligible investments such as U.S. government obligations, commercial paper, and money market funds.
• · The company is a closed-end management investment company regulated as a business development company under the 1940 Act.
• · The agreement includes a limited recourse clause (Section 25).

07-07-2026

Oceaneering International increased its senior secured revolving credit facility from $215 million to $345 million and extended the maturity from April 2027 to July 2031. The facility also allows for an additional $85 million upsizing and $150 million in letter of credit availability. CFO Mike Sumruld stated the amendment provides additional financial flexibility to support operations, strategic priorities, and growth initiatives.

• · Maturity date extended from April 2027 to July 2031.
• · Credit facility includes ability to upsize by an additional $85 million.
• · Letter of credit sublimit of $150 million.
• · Amendment supported by both long-standing and new participating lenders.
• · Oceaneering serves offshore energy, defense, aerospace, and manufacturing industries.

07-07-2026

Z Squared Inc. (formerly Coeptis Therapeutics Holdings, Inc.) entered into a Sales Agreement with Roth Capital Partners, LLC on July 6, 2026, to sell up to $300,000,000 of its common stock in an at-the-market offering. The company will pay a 3.0% commission on sales and has filed an automatic shelf registration statement (Form S-3) to facilitate the offering. No prior period comparisons are available as this is a new agreement.

• · The Sales Agreement allows sales through The Nasdaq Global Market or other methods, including negotiated transactions.
• · The company may also sell shares directly to Roth Capital as principal under separate terms agreements.
• · The agreement includes customary representations, warranties, indemnification, and termination provisions (5 days' notice by either party).
• · The Registration Statement (File No. 333-297288) was filed and became effective automatically on July 7, 2026.
• · The opinion of counsel (Zarif Law Group P.C.) on the legality of the Placement Shares is filed as Exhibit 5.1.

07-07-2026

Oportun Financial Corporation entered into a Program Management Agreement with Column National Association on June 30, 2026, to establish a new lending program. Under the agreement, Column will originate unsecured personal loans, and Oportun will provide platform services including marketing, processing, and servicing. The agreement has a four-year initial term with automatic renewals.

• · The agreement includes exclusivity provisions for specified loan products and future financial products, subject to existing bank partner rights.
• · Oportun can purchase loans originated by Column, except those retained by Column.
• · The agreement contains compliance, oversight, audit, reporting, reserve, information-security, indemnification, termination, and wind-down provisions.

07-07-2026

UGI Energy Services, LLC, a subsidiary of UGI Corp, entered into a Fourth Amendment to its Credit Agreement on June 30, 2026, securing $774 million in Refinancing Term Loans from HSBC Bank USA, N.A. to refinance all outstanding Term Loans. The amendment includes a cashless roll option for certain existing lenders and extends the credit facility under modified terms. No negative or flat performance metrics are present in this filing, as it solely concerns a debt refinancing transaction.

• · The amendment was executed on June 30, 2026, and filed on July 7, 2026.
• · The 2026 Refinancing Term Loans refinance all Term Loans outstanding immediately prior to the amendment's effectiveness.
• · Certain existing lenders may convert their Refinanced Term Loans to 2026 Refinancing Term Loans via a cashless roll, with the aggregate commitment equal to the amount of Refinanced Term Loans less those cashlessly rolled.
• · HSBC Securities (USA) Inc. acted as lead arranger and bookrunner.
• · The amendment includes representations and warranties, conditions precedent, and requires payment of an amortization payment due June 30, 2026.

07-07-2026

The Oncology Institute (TOI) completed a strategic refinancing by repaying its $86 million Deerfield convertible note with a new $75 million term loan from OrbiMed maturing in 2031 and approximately $11 million in cash, without issuing new equity. The transaction improves liquidity, extends debt maturities, and strengthens the balance sheet, though the new debt is $11 million smaller than the prior note, reflecting a reduction in total debt outstanding.

• · The new OrbiMed term loan matures in 2031, significantly extending debt maturities.
• · No additional equity was raised, avoiding dilution for existing shareholders.
• · TOI operates over 100 clinics and network locations across five states with over 400 clinicians.
• · TOI serves approximately 2.0 million patients.

07-07-2026

PMGC Holdings Inc. (ELAB) announced that its wholly owned subsidiary, NorthStrive Defense Tech LLC, entered into an exclusive worldwide license agreement for U.S. Patent No. 12,291,334 and associated know-how in aerospace and defense technologies. The licensee must pay an undisclosed non-refundable license issue fee and annual maintenance fees, plus royalties and sublicense payments. Key diligence milestones are projected in good faith, but no specific revenue or performance data is provided, making the near-term financial impact unclear.

• · The agreement was effective June 30, 2026, and filed on July 7, 2026.
• · NorthStrive Defense Tech has the right to grant sublicenses subject to license terms.
• · Failure to meet a milestone does not automatically breach the agreement if the licensee timely requests an extension.
• · Term runs until the last-to-expire Royalty Term (later of patent expiry or 12 years from first Net Sale).
• · Licensee may terminate without cause after the first anniversary with 60 days' notice.

07-07-2026

Iridium Communications Inc. completed its acquisition of Aireon LLC, operator of the world's only space-based ADS-B air traffic surveillance system, for an undisclosed amount. The acquisition expands Iridium's role in aviation by combining Aireon's surveillance and intelligence services with Iridium's global satellite network and PNT capabilities. Don Thoma will continue as Aireon's CEO, reporting to Iridium CEO Matt Desch, ensuring leadership continuity.

• · Aireon will operate as a wholly owned subsidiary of Iridium.
• · The acquisition was completed on July 6, 2026.
• · Iridium serves millions of customers worldwide through an ecosystem of more than 500 technology and distribution partners.
• · The press release includes forward-looking statements regarding expected synergies and integration risks.

07-07-2026

Core Molding Technologies amended and extended its credit facility through 2031, consisting of a $50 million delayed draw term loan and a $50 million revolving credit facility with a covenant-light structure and reduced cost of capital. However, the company reported a net loss in operating cash flow of $(9.2) million for Q1 2026 compared to positive $6.1 million in Q1 2025, and net income declined 72% YoY to $0.6 million from $2.2 million, reflecting significant operational headwinds despite the improved financing flexibility.

• · The credit facility bears interest at SOFR plus an applicable margin ranging from 1.50% to 3.75%, based on leverage ratio.
• · Q1 2026 net cash used in operating activities was $(9.2) million vs. $6.1 million provided in Q1 2025, driven by a $22.7 million increase in accounts receivable.
• · Capital expenditures in Q1 2026 were $3.8 million, up from $1.8 million in Q1 2025.
• · Mexico expansion related costs of $2.1 million and succession plan costs of $0.9 million were excluded from Adjusted EBITDA in Q1 2026.
• · Debt to trailing twelve months Adjusted EBITDA was a low 0.62x as of March 31, 2026.
• · Trailing twelve months return on capital employed was 6.8% (7.9% excluding cash).
• · The company repurchased $0.5 million of treasury stock in Q1 2026, down from $0.9 million in Q1 2025.

07-07-2026

Postal Realty Trust, Inc. (NYSE: PSTL) announced a recast and expansion of its revolving credit facility, increasing total unsecured credit facilities to $615 million (from $555 million) with a new $335 million accordion feature. The recast, effective July 2, 2026, extends weighted average maturity by about one year and achieves a 30 basis point improvement in pricing, now tied to an investment grade grid from Moody’s, S&P, and Fitch. While total term loans increased from $305 million to $340 million, the weighted average interest rate on term loans actually rose slightly (e.g., the 2028 term loan rate increased to 4.94% from 4.78%), reflecting mixed cost-of-debt dynamics.

• · Weighted average maturity extended by approximately one year.
• · Company received a BBB investment grade rating from KBRA in February 2026.
• · Revolver matures in November 2030; 2028 term loan matures Feb 2028; 2029 term loan matures Feb 2029; 2031 term loan matures Jan 2031.
• · The fixed rate on the $75M portion of the 2028 term loan increased to 4.94% from 4.78% (prior rate).
• · The 2029 term loan ($100M at 4.14%) and 2031 term loan ($150M at 3.86%) are new, partially replacing the prior 2030 term loan ($115M at 3.81%).

07-07-2026

Polar Power, Inc. issued a $275,000 convertible promissory note to Mayers Ventures LLC on June 30, 2026, with a 10% original issue discount (net proceeds of $250,000) and 10% PIK interest. The note matures on December 30, 2027, and is initially unsecured but will become secured by a springing lien subordinated to existing senior lenders Pinnacle Bank and Monroe Street Partners. Proceeds are for working capital and general corporate purposes.

• · The note is a senior unsecured obligation initially, but will become secured by a springing lien upon execution of subordination agreements with Pinnacle Bank and Monroe Street Partners.
• · Prepayment is allowed at 115% of the principal amount (10% premium) with 10 trading days' notice, provided no event of default has occurred.
• · Events of default include failure to pay principal or interest after a 3-business-day cure period, breach of covenants, failure to deliver conversion shares, bankruptcy-related events, and judgments exceeding $500,000.
• · The note is convertible into common stock (conversion terms referenced in Article 4, not fully detailed in this excerpt).
• · The company must maintain a required minimum of authorized common stock to satisfy full conversion of the note.

07-07-2026

Golub Capital Private Credit Fund executed a Fourth Amendment to its Revolving Loan Agreement with GC Advisors LLC, dated July 2, 2026, modestly updating documentation (e.g., removal of a note requirement, procedural clarifications). The amendment maintains the existing $300 million revolving credit commitment, with no change in loan terms (interest at the Applicable Federal Rate, no premium or penalty on prepayment) and includes standard representations that no Event of Default has occurred. This filing reflects a routine, non-material housekeeping adjustment: no new funding or material changes to the facility were introduced.

07-07-2026

CDT Equity Inc. issued a $1,971,000 senior secured convertible note to J.J. Astor & Co. on June 11, 2026, with a funding amount of $1,401,600 after a $58,400 origination fee. The note requires 24 weekly installments of $82,125 starting July 10, 2026, maturing December 18, 2026, and carries a default interest rate of 19% per annum with a 120% default principal multiplier. The company's short-term debt structure and high default penalties indicate significant financial strain.

• · The note is secured and convertible, with conversion terms defined in the Loan Agreement.
• · Default triggers a Default Amount equal to 120% of the Outstanding Principal Amount plus default interest at 19% per annum compounded daily.
• · The note is unregistered and subject to restrictions under the Securities Act of 1933.
• · The Loan Agreement was originally dated June 11, 2026 and amended on June 30, 2026.
• · The company is a Delaware corporation.

07-07-2026

Vivos Therapeutics raised approximately $2.1 million in a PIPE offering on June 30, 2026, selling 3,608,496 units at $0.582 per unit to V-Co Investors 4 LLC and Bigger Capital Fund, LP. The offering included Series A Convertible Preferred Stock, warrants, and transferable subscription rights, with $1.0 million in cash proceeds and $1.0 million from conversion of a prior bridge note. However, the company received only $1.0 million in new cash, and the CEO's indirect participation was a modest $50,000, indicating limited insider confidence.

• · The PIPE offering closed on June 30, 2026, with no placement agent used.
• · Warrants have a five-year term, exercise price of $0.456 per share, and become exercisable immediately.
• · Beneficial ownership limitations: V-Co 4 and affiliates capped at 19.99%; Bigger capped at 9.99% (or 4.99% at Bigger's election).
• · Company must file a resale registration statement within 45 days of closing and use best efforts to have it effective within 90 days.
• · Preferred stock has no voting rights except on matters affecting its preferences, and no price-based reset or ratchet on conversion ratio.
• · The Rights (subscription rights) were not issued at closing; their issuance is conditioned on SEC effectiveness of a Rights Registration Statement.

07-07-2026

Semnur Pharmaceuticals, a majority-owned subsidiary of Scilex Holding Company, announced the signing of a binding term sheet for a $100 million strategic investment from iHolding Group LLP, a Kazakhstan-based private investment group. The investment, at $10.00 per share for approximately 10 million newly issued shares, is intended to fund the Phase 3 program for SEMDEXA (SP-102), product development, acquisitions, and working capital. However, the transaction remains subject to due diligence, definitive agreements, board approvals, and regulatory clearances, with no guarantee of closing.

• · Semnur is a clinical late-stage specialty pharmaceutical company focused on non-opioid pain therapies.
• · SEMDEXA has FDA Fast Track designation and is in advanced Phase 3 development for chronic radicular pain/sciatica.
• · iHolding Group LLP is headquartered in Almaty, Republic of Kazakhstan.
• · The proposed investment is aligned with iHolding's strategy to establish Kazakhstan as a regional hub for pharmaceutical manufacturing and R&D.
• · The transaction is subject to customary due diligence, definitive agreements, board approvals, and regulatory approvals.
• · Semnur is a majority-owned subsidiary of Scilex Holding Company, which also markets ZTlido, ELYXYB, and Gloperba.

07-07-2026

DevvStream Corp. (DEVS) entered into a definitive Securities Purchase Agreement (SPA) with EEME Energy SPV I, LLC and Southern Energy Renewables, Inc. on June 30, 2026, superseding a prior term sheet. The SPA provides for a $6,000,000 investment, with $5,000,000 advanced to Southern for a business combination and $1,000,000 for the purchase of DevvStream common shares at $0.28683 per share, resulting in 3,486,386 shares. As of the SPA date, only $1,500,000 of the total investment has been funded, with the remaining $4,500,000 due by September 30, 2026, and the business combination is subject to closing conditions, including the BCA's completion.

• · The SPA supersedes the prior binding term sheet dated June 3, 2026.
• · If the BCA is terminated before closing, DevvStream will issue 50,000 Series A Non-Voting Preferred Shares to EEME, which are senior to common shares in liquidation but carry no dividends and are non-convertible.
• · EEME has agreed to vote its securities in favor of the Domestication and DevvStream Merger under the BCA.
• · The common share purchase price of $0.28683 represents a 10% discount to the 15-day VWAP preceding the agreement date.
• · Payment for the common shares may be made in tranches, with the balance due by September 30, 2026.
• · The remaining $4,500,000 of the EEME Investment is to be funded at one or more subsequent closings on mutually agreed dates on or before September 30, 2026.

07-07-2026

Lifeway Foods, Inc. entered into a Master Security Agreement with CIBC Bank USA on June 30, 2026, to finance the acquisition of equipment. The agreement establishes general terms for secured loan transactions, with each loan evidenced by a separate Schedule. No specific financial amounts or equipment details are disclosed in this filing.

• · The MSA includes standard representations, warranties, and covenants regarding Customer's organization, authority, financial reporting, and compliance with laws.
• · Customer must provide annual audited financial statements within 90 days after fiscal year-end and quarterly unaudited statements within 45 days after quarter-end.
• · Lender has the right to inspect Collateral and books annually, or at any time after a Default.
• · Customer must notify Lender at least 30 days before any change in name, jurisdiction, or form of organization.
• · The agreement prohibits Customer from creating liens on the Equipment except in favor of Lender.